Gianmichele Meucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gianmichele Meucci has a total of 393 co-authors. Here are the top co-authors by number of shared publications:
- Franco Radaelli
Gastroenterology Department, Valduce Hospital, Como, Italy
14 shared publications - Simone Saibeni
IBD Unit, Gastroenterology Unit, Rho Hospital, ASST Rhodense , Rho
14 shared publications Maurizio Vecchi
Federico II University, Gastroenterology, Naples, Italy
11 shared publications- Vittorio Terruzzi
Division of Gastroenterology, Valduce Hospital, Como, Italy
11 shared publications Giorgio Minoli
8 shared publicationsRoberto de Franchis
Gastroenterology and Gastrointestinal Endoscopy Service, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
8 shared publications
Latest Publications
- Open Access
Incident Colorectal Cancer in Inflammatory Bowel Disease
Colorectal cancer (CRC) risk is increased in Inflammatory Bowel Disease (IBD) and surveillance needs to be tailored according to individual risk. The open issues include the role of the characteristics of IBD and CRC in determining the long-term outcome. These issues were assessed in our multicenter study, including a cohort of 56 IBD patients with incident CRC. The clinical and histopathological features of IBD patients and of CRC were recorded. Incident CRC in IBD occurred at a young age (≤40 years) in 25% of patients (median age 55.5 (22–76)). Mucinous signet-ring carcinoma was detected in 6 out of the 56 (10.7%) patients, including 4 with Ulcerative Colitis (UC) and 2 with Crohn’s disease (CD). CRC was more frequently diagnosed by colonoscopy in UC (85.4% vs. 50%; p = 0.01) and by imaging in Crohn’s Disease CD (5.8% vs. 31.8%; p = 0.02). At onset, CRC-related symptoms occurred in 29 (51.9%) IBD patients. The time interval from the diagnosis of IBD to CRC was shorter in UC and CD patients with >40 years (p = 0.002; p = 0.01). CRC-related death occurred in 10 (29.4%) UC and in 6 (27.2%) CD patients (p = 0.89), with a short time interval from CRC to death (UC vs. CD: 6.5 (1–68) vs. 14.5 (8–40); p = 0.85; IBD: 12 months (1–68)). CRC occurring at a young age, a short time interval from the diagnosis of IBD to CRC-related death in the elderly, CRC-symptoms often mimicking IBD relapse and the observed high mortality rate may support the need of closer surveillance intervals in subgroups of patients.
Open AccessIncident Colorectal Cancer in Inflammatory Bowel Disease
Colorectal cancer (CRC) risk is increased in Inflammatory Bowel Disease (IBD) and surveillance needs to be tailored according to individual risk. The open issues include the role of the characteristics of IBD and CRC in determining the long-term outcome. These issues were assessed in our multicenter study, including a cohort of 56 IBD patients with incident CRC. The clinical and histopathological features of IBD patients and of CRC were recorded. Incident CRC in IBD occurred at a young age (≤40 years) in 25% of patients (median age 55.5 (22–76)). Mucinous signet-ring carcinoma was detected in 6 out of the 56 (10.7%) patients, including 4 with Ulcerative Colitis (UC) and 2 with Crohn’s disease (CD). CRC was more frequently diagnosed by colonoscopy in UC (85.4% vs. 50%; p = 0.01) and by imaging in Crohn’s Disease CD (5.8% vs. 31.8%; p = 0.02). At onset, CRC-related symptoms occurred in 29 (51.9%) IBD patients. The time interval from the diagnosis of IBD to CRC was shorter in UC and CD patients with >40 years (p = 0.002; p = 0.01). CRC-related death occurred in 10 (29.4%) UC and in 6 (27.2%) CD patients (p = 0.89), with a short time interval from CRC to death (UC vs. CD: 6.5 (1–68) vs. 14.5 (8–40); p = 0.85; IBD: 12 months (1–68)). CRC occurring at a young age, a short time interval from the diagnosis of IBD to CRC-related death in the elderly, CRC-symptoms often mimicking IBD relapse and the observed high mortality rate may support the need of closer surveillance intervals in subgroups of patients.
- 1 October 2019
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (10) , 1380-1387
Complications and early mortality in percutaneous endoscopic gastrostomy placement in lombardy: A multicenter prospective cohort study
- 1 October 2019
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (10) , 1380-1387
Complications and early mortality in percutaneous endoscopic gastrostomy placement in lombardy: A multicenter prospective cohort study
- 18 August 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 25 (3) , 568-579
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn’s disease [CD]) were enrolled. Four hundred fifty-nine patients were naïve to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with baseline. In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.
- 18 August 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 25 (3) , 568-579
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn’s disease [CD]) were enrolled. Four hundred fifty-nine patients were naïve to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with baseline. In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.
- 1 October 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (10) , 1092-1097
The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey
- 1 October 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (10) , 1092-1097
The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey
- 1 April 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (4) , 338-358
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
- 1 April 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (4) , 338-358
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
- 14 November 2016
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 11 (1) , 33-41
The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology
Ulcerative colitis (uc) is a chronic condition and for the vast majority of patients, life-long treatment is required. low adherence to therapy is an emerging issue. since low adherence is associated with poor clinical outcomes and increased costs, it is becoming crucial to identify strategies in order to improve it. Areas covered: We performed literature searches in PubMed using the terms 'adherence', 'mesalamine', 'budesonide MMX', 'MMX technology' in combination with 'ulcerative colitis'. Firstly, we present the key-concepts of therapy for UC and discuss the problem of the adherence and how to measure it. Then, we provide data on the extent of the problem and the causes and consequences from clinical and economic point of views. Finally, we focus on treatment-related variables associated with non-adherence and treatment-related strategies to improve adherence, paying particular attention to Multi Matrix system (MMX) technology applied to mesalazine and budesonide. Expert commentary: The pharmaceutical industry and scientific community are making efforts to simplify treatments for UC. MMX technology, which allows a reduction in the number of pills to be taken and daily administrations, may facilitate adherence to treatment and carry further clinical benefits.
- 14 November 2016
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 11 (1) , 33-41
The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology
Ulcerative colitis (uc) is a chronic condition and for the vast majority of patients, life-long treatment is required. low adherence to therapy is an emerging issue. since low adherence is associated with poor clinical outcomes and increased costs, it is becoming crucial to identify strategies in order to improve it. Areas covered: We performed literature searches in PubMed using the terms 'adherence', 'mesalamine', 'budesonide MMX', 'MMX technology' in combination with 'ulcerative colitis'. Firstly, we present the key-concepts of therapy for UC and discuss the problem of the adherence and how to measure it. Then, we provide data on the extent of the problem and the causes and consequences from clinical and economic point of views. Finally, we focus on treatment-related variables associated with non-adherence and treatment-related strategies to improve adherence, paying particular attention to Multi Matrix system (MMX) technology applied to mesalazine and budesonide. Expert commentary: The pharmaceutical industry and scientific community are making efforts to simplify treatments for UC. MMX technology, which allows a reduction in the number of pills to be taken and daily administrations, may facilitate adherence to treatment and carry further clinical benefits.
- 1 March 2016
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 10 (8) , 913-924
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study
Background and Aims: Cancer risk in Inflammatory Bowel Disease (IBD) is still debated. In a prospective, multicenter, nested case-control study, we aimed to characterize incident cases of cancer in IBD. The role of immunomodulators versus clinical characteristics of IBD as risk factors for cancer was also investigated. Materials and Methods: From January 2012 to December 2014, each IBD patient with incident cancer was matched with 2 IBD patients without cancer for: IBD type, gender, age. Risk factors were assessed by multivariate regression analysis. Results. IBD patients considered were 44,619: 21,953 Crohn’s Disease (CD), 22,666 Ulcerative Colitis (UC). Cancer occurred in 174 patients: 99 CD (CD-K), 75 UC (UC-K). Controls included 198 CD (CD-C), 150 UC (UC-C). Cancer incidence in IBD was 3.9/1000, higher in CD (4.5/1000 [99/21,953]) than in UC (3.3/1000 [75/22,666]; p=0.042). Cancers involved: digestive system (36.8%), skin (13.2%), urinary tract (12.1%), lung (8.6%), breast (8%), genital tract (6.9%), thyroid (4.6%), lymphoma (3.5%), others (6.3%). In CD, penetrating behavior and combined thiopurines and TNFα antagonists were risk factors for cancer overall (OR [95% CI]: 2.33 [1.01-5.47]; 1.97 [1.1-3.5]) and for extracolonic cancers (OR 3.9 [1.56-10.1]; 2.15 [1.17-4.1]). In UC, risk factors were: pancolitis and disease-related surgery for cancer overall (OR: 2.52 [1.26-5.1]; 5.09 [1.73-17.1]); disease-related surgery for CRC (OR 3.6 [1.0-12]); extensive and left-sided vs distal UC for extracolonic cancers (OR: 2.55 [1.15-5.9]; 2.6 [1.04-6.6]). Conclusions: In a multicenter study, penetrating CD and extensive UC were risk factors for cancer overall. Cancer incidence was higher in CD than in UC.
- 1 March 2016
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 10 (8) , 913-924
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study
Background and Aims: Cancer risk in Inflammatory Bowel Disease (IBD) is still debated. In a prospective, multicenter, nested case-control study, we aimed to characterize incident cases of cancer in IBD. The role of immunomodulators versus clinical characteristics of IBD as risk factors for cancer was also investigated. Materials and Methods: From January 2012 to December 2014, each IBD patient with incident cancer was matched with 2 IBD patients without cancer for: IBD type, gender, age. Risk factors were assessed by multivariate regression analysis. Results. IBD patients considered were 44,619: 21,953 Crohn’s Disease (CD), 22,666 Ulcerative Colitis (UC). Cancer occurred in 174 patients: 99 CD (CD-K), 75 UC (UC-K). Controls included 198 CD (CD-C), 150 UC (UC-C). Cancer incidence in IBD was 3.9/1000, higher in CD (4.5/1000 [99/21,953]) than in UC (3.3/1000 [75/22,666]; p=0.042). Cancers involved: digestive system (36.8%), skin (13.2%), urinary tract (12.1%), lung (8.6%), breast (8%), genital tract (6.9%), thyroid (4.6%), lymphoma (3.5%), others (6.3%). In CD, penetrating behavior and combined thiopurines and TNFα antagonists were risk factors for cancer overall (OR [95% CI]: 2.33 [1.01-5.47]; 1.97 [1.1-3.5]) and for extracolonic cancers (OR 3.9 [1.56-10.1]; 2.15 [1.17-4.1]). In UC, risk factors were: pancolitis and disease-related surgery for cancer overall (OR: 2.52 [1.26-5.1]; 5.09 [1.73-17.1]); disease-related surgery for CRC (OR 3.6 [1.0-12]); extensive and left-sided vs distal UC for extracolonic cancers (OR: 2.55 [1.15-5.9]; 2.6 [1.04-6.6]). Conclusions: In a multicenter study, penetrating CD and extensive UC were risk factors for cancer overall. Cancer incidence was higher in CD than in UC.
- 1 February 2015
- Published by Elsevier in Digestive and Liver Disease
- Vol. 47 (2) , 170-173
How thiopurines are used for the treatment of inflammatory bowel diseases: An Italian survey
- 1 February 2015
- Published by Elsevier in Digestive and Liver Disease
- Vol. 47 (2) , 170-173
How thiopurines are used for the treatment of inflammatory bowel diseases: An Italian survey
- 1 August 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (8) , 852-858
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall colectomy-free survival and the identification of predictors of colectomy. The 3- and 12-month colectomy rates were 18.6% (95%CI 11.8%-26.9%) and 25.6% (95%CI 17.9%-34.7%) respectively. High CRP values and severe endoscopic lesions were associated with the risk of colectomy: Risk Ratio (RR)=2.15 (95%CI 1.05-4.36), and RR=5.13 (95%CI 1.55-16.96), respectively. In patients escaping early colectomy, the probability of a colectomy-free course at 12, 24, 36 and 60months was 91%, 85%, 81% and 73%, respectively. Endoscopic severity was the only predictor of long term colectomy (RR=7.0; 95%CI 1.09-44.7). Adverse events occurred in 16 patients (14%); there was one death (0.88%) due to pulmonary abscess. Infliximab is an effective and safe rescue therapy for severe corticosteroid-refractory ulcerative colitis. A three-dose induction regimen seems to be the treatment of choice for preventing early colectomy. Severe endoscopic lesions appear to be predictor of short- and long-term colectomy.
- 1 August 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (8) , 852-858
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall colectomy-free survival and the identification of predictors of colectomy. The 3- and 12-month colectomy rates were 18.6% (95%CI 11.8%-26.9%) and 25.6% (95%CI 17.9%-34.7%) respectively. High CRP values and severe endoscopic lesions were associated with the risk of colectomy: Risk Ratio (RR)=2.15 (95%CI 1.05-4.36), and RR=5.13 (95%CI 1.55-16.96), respectively. In patients escaping early colectomy, the probability of a colectomy-free course at 12, 24, 36 and 60months was 91%, 85%, 81% and 73%, respectively. Endoscopic severity was the only predictor of long term colectomy (RR=7.0; 95%CI 1.09-44.7). Adverse events occurred in 16 patients (14%); there was one death (0.88%) due to pulmonary abscess. Infliximab is an effective and safe rescue therapy for severe corticosteroid-refractory ulcerative colitis. A three-dose induction regimen seems to be the treatment of choice for preventing early colectomy. Severe endoscopic lesions appear to be predictor of short- and long-term colectomy.
- 31 May 2014
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 8 (8) , 949-962
Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?
At present, therapy of inflammatory bowel disease is still far from being fully satisfactory; old drugs like steroids, for instance, still represent a cornerstone in the treatment of active disease despite their associated important side effects and incomplete clinical efficacy. In the last years, new therapeutic strategies have been suggested in order to avoid or at least limit steroids use and in this direction the so-called low bioavailability steroids appeared to be a promising therapeutic weapon; however, some grey areas about their real utility and manner of use still remain. The aim of this review is to evaluate the available evidence about the use of oral budesonide and beclomethasone dipropionate in inflammatory bowel disease, to critically assess their current position in the therapeutic algorithm of these diseases and to give simple and practical indications for their use in every-day clinical practice.
- 31 May 2014
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 8 (8) , 949-962
Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?
At present, therapy of inflammatory bowel disease is still far from being fully satisfactory; old drugs like steroids, for instance, still represent a cornerstone in the treatment of active disease despite their associated important side effects and incomplete clinical efficacy. In the last years, new therapeutic strategies have been suggested in order to avoid or at least limit steroids use and in this direction the so-called low bioavailability steroids appeared to be a promising therapeutic weapon; however, some grey areas about their real utility and manner of use still remain. The aim of this review is to evaluate the available evidence about the use of oral budesonide and beclomethasone dipropionate in inflammatory bowel disease, to critically assess their current position in the therapeutic algorithm of these diseases and to give simple and practical indications for their use in every-day clinical practice.